TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status (TCM-HMB-PF)
13 de maio de 2026 atualizado por: Jui-Shan Lin, MD, Tri-Service General Hospital
Effects of Traditional Chinese Medicine (TCM) Formula vs. HMB on Muscle Strength and Bone Status in Pre-Frail Elders: A Comparative Study
The purpose of this study is to compare the effects of a standardized Traditional Chinese Medicine (TCM) formula versus beta-hydroxy-beta-methylbutyrate (HMB) on muscle strength and bone health in pre-frail older adults .
Pre-frailty is a critical stage where functional decline may still be reversed through proper intervention.
The study will enroll 90 participants aged 65 years or older who meet the criteria for pre-frailty.
Participants will be randomly assigned to either the TCM group (receiving a standardized herbal powder formula) or the HMB group (receiving nutritional supplement tablets) for 24 weeks .
The primary objective is to evaluate the change in handgrip strength from baseline to Week 12 .
Researchers will also assess changes in skeletal muscle mass, bone mineral density, and overall physical performance .
The goal is to determine if the TCM formula is an effective alternative or complementary intervention for managing geriatric frailty.
Visão geral do estudo
Status
Status
Recrutamento
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is a randomized, open-label, parallel-group comparative study designed to evaluate the clinical efficacy and safety of a standardized Traditional Chinese Medicine formula versus beta-hydroxy-beta-methylbutyrate supplementation in pre-frail older adults .
Pre-frailty is identified as a reversible stage between robust health and frailty.
This study aims to provide clinical evidence for the Traditional Chinese Medicine formula as an intervention to improve muscle strength, bone health, and physical function.
Eligible participants aged 65 years or older who meet 1 to 2 of the 5 Fried frailty phenotype criteria will be randomized in a 1 to 1 ratio.
The total study duration for each participant is approximately 26 weeks, including a screening period and a 24-week intervention period.
Participants in the Traditional Chinese Medicine group receive a standardized herbal powder formula designed to tonify Qi, Blood, Liver, and Kidney.
The total daily dosage is 18 grams, administered as 9 grams twice daily, taken 30 minutes before breakfast and lunch.
Participants in the HMB group receive a total daily dose of 3 grams of beta-hydroxy-beta-methylbutyrate, administered as two 0.75-gram tablets twice daily after breakfast and lunch.
The primary endpoint is the change from baseline in handgrip strength at Week 12 .
Secondary endpoints assessed at Week 12 and Week 24 include changes in skeletal muscle mass, bone mineral density, body fat percentage, gait speed using a 6-meter test, Timed Up and Go test, Five Times Sit-to-Stand test, Fried frailty phenotype status, Clinical Frailty Scale scores, and SF-12 quality of life scores .
Safety is monitored throughout the study by assessing adverse events and changes in laboratory parameters, including complete blood count, liver and renal function, and urinalysis .
A total of 90 participants (45 per group) is required based on a non-inferiority t-test for the primary endpoint.
The calculation assumed a power of 80 percent and a one-sided significance level of 0.025, accounting for an estimated 20 percent dropout rate.
Tipo de estudo
Tipo de estudo
Intervencional
Inscrição (Estimado)
Inscrição
90
Estágio
Estágio
- Fase 2
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
Contato de estudo
- Nome: Jui-Shan Lin, MD
- Número de telefone: 24260 886-2-87923311
- E-mail: sunnylin@mail.ndmutsgh.edu.tw
Estude backup de contato
- Nome: Li-Wei Wu, MD
- Número de telefone: 12618 886-2-87923311
- E-mail: liweiwu@mail.ndmutsgh.edu.tw
Locais de estudo
-
-
-
Taipei, Taiwan, 114202
- Recrutamento
- Tri-Service General Hospital
-
Contato:
- Jui-Shan Lin, MD
- Número de telefone: 24260 886-2-87923311
- E-mail: sunnylin@mail.ndmutsgh.edu.tw
-
Investigador principal:
- Jui-Shan Lin, MD
-
Subinvestigador:
- Li-Wei Wu, MD
-
Subinvestigador:
- Sui-Lung Su, Prof.
-
Subinvestigador:
- Wen-Hui Fang, MD
-
Subinvestigador:
- Yaw-Wen Chang, MD
-
Subinvestigador:
- Tung-Wei Kao, MD
-
Subinvestigador:
- Hung-Yi Chen, MD
-
Subinvestigador:
- Yan-Ru Wang, MD
-
Subinvestigador:
- Yu-Heng Wang, MD
-
Subinvestigador:
- Po-Han Lin, MD
-
Subinvestigador:
- Tao-Chun Peng, MD
-
Subinvestigador:
- Ting-Ching Chen, MD
-
Subinvestigador:
- Wan-Ting Soong, MD
-
Subinvestigador:
- Yu-Ting Cheng, MD
-
Subinvestigador:
- Yi-Ru Lei, MD
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Male or female participants aged 65 years or older at the time of screening.
- Body Mass Index less than 30 kilograms per square meter.
- Identified as pre-frail according to the Fried frailty phenotype, meeting 1 to 2 of the following 5 criteria: 1) Hand grip strength below specific thresholds based on gender and Body Mass Index. For males, Body Mass Index 24 or less is 29 kilograms or less, Body Mass Index 24.1 to 28 is 30 kilograms or less, Body Mass Index greater than 28 is 32 kilograms or less. For females, Body Mass Index 23 or less is 17 kilograms or less, Body Mass Index 23.1 to 26 is 17.3 kilograms or less, Body Mass Index 26.1 to 29 is 18 kilograms or less, Body Mass Index greater than 29 is 21 kilograms or less. 2) Slow walking speed. For a 4-meter distance, walking time of 7 seconds or more for males 173 centimeters or shorter, or 6 seconds or more for males taller than 173 centimeters. For females 159 centimeters or shorter, 7 seconds or more, or 6 seconds or more for females taller than 159 centimeters. 3) Self-reported exhaustion. Answering 3 days or more per week to either feeling that everything was an effort or could not get going in the past week. 4) Unintentional weight loss. Loss of 3 kilograms or more or more than 5 percent of body weight in the past year. 5) Low physical activity. Weekly energy expenditure less than 383 kilocalories for males or less than 270 kilocalories for females.
- Ability to safely complete a 6-meter walk test in a single attempt without assistance or using only simple aids such as a cane.
- Clinically stable condition allowing for follow-up visits every 4 weeks and participation in all study-related assessments.
- Willingness to provide existing test data from within 90 days prior to randomization, including Bone Mineral Density by DXA and serum biochemistry or urinalysis results.
- Sufficient cognitive function to understand the study and sign the informed consent form, or with the assistance of a legal representative.
- Willingness to maintain existing diet and exercise habits during the study and not start high-intensity exercise programs or large amounts of nutritional supplements.
Exclusion Criteria:
- Major acute illness such as acute myocardial infarction, pneumonia, or acute stroke within 2 weeks prior to screening.
- Major organ dysfunction, including renal function with estimated glomerular filtration rate less than 45 milliliters per minute per 1.73 square meters within 1 month prior to screening, liver function with AST or ALT greater than 3 times the upper limit of normal within 1 month prior to screening, NYHA Class III or IV heart failure, or severe COPD requiring long-term oxygen therapy.
- Unplanned hospitalization within 1 month prior to screening, or major surgery with incomplete functional recovery within 3 months prior to screening.
- Current malignant tumor under treatment, or less than 12 months since the completion of cancer treatment.
- Use of supplements containing the same ingredients as the study interventions, or products that may affect the primary endpoint including HMB, creatine, branched-chain amino acids, or high-dose protein powder within 4 weeks prior to screening.
- Known significant clinical allergy or hypersensitivity to any components of the study formula or HMB nutritional supplement.
- Moderate to severe dementia, severe depression, or other psychiatric disorders resulting in inability to cooperate without a legal representative.
- Participation in other interventional clinical trials involving drugs, biologics, or nutritional supplements within 3 months prior to screening.
- New initiation or dose adjustment of medications affecting muscle or bone metabolism within 3 months prior to screening, including systemic glucocorticoids, anabolic steroids, testosterone, or growth hormones.
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for the study due to safety or compliance concerns.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
2
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Experimental: TCM Group
Participants will receive a standardized Traditional Chinese Medicine herbal powder formula.
This formula is designed to tonify Qi, Blood, Liver, and Kidney to enhance physical function in elders.
The daily dosage is 18 grams, administered as one 9-gram sachet twice daily.
It is taken 30 minutes before breakfast and lunch for 24 consecutive weeks.
|
A scientific TCM herbal powder formula prepared by the hospital pharmacy.
The formula consists of 10 botanical ingredients focused on tonifying Qi, Blood, Liver, and Kidney.
Participants will receive a total daily dose of 18 grams, administered as 9 grams twice daily (BID), 30 minutes before breakfast and lunch.
Outros nomes:
|
|
Comparador Ativo: Active Comparator: HMB Group
Participants will receive beta-hydroxy-beta-methylbutyrate (HMB) as an active control.
The intervention consists of a total daily dose of 3 grams, administered as two 0.75-gram tablets twice daily.
The tablets are to be taken after breakfast and lunch for 24 consecutive weeks.
|
The active ingredient is beta-hydroxy-beta-methylbutyrate (HMB), provided in 0.75g tablets.
Participants will take 2 tablets twice daily (BID) after breakfast and lunch, resulting in a total daily dose of 3 grams.
This is a common clinical dose used as a nutritional intervention for muscle strength and physical performance.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in Hand Grip Strength at Week 12
Prazo: Baseline and Week 12
|
Hand grip strength is used as a functional biomarker to reflect overall muscle strength.
Measurement will be performed using a standardized JAMAR dynamometer.
Participants will follow a standardized procedure: seated position, elbow flexed at 90 degrees, with the forearm in a neutral position using the dominant hand.
The "Change" is calculated as the value at Week 12 minus the baseline value .
Higher values indicate improved muscle strength.
|
Baseline and Week 12
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Hand Grip Strength at Week 24
Prazo: Baseline and Week 24.
|
Change from baseline in hand grip strength at Week 24.
Measurement is performed using a standardized JAMAR dynamometer with the dominant hand.
Higher values indicate better muscle strength.
|
Baseline and Week 24.
|
|
Change in Skeletal Muscle Mass
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in skeletal muscle mass measured by Bioelectrical Impedance Analysis (BIA).
This reflects structural changes in muscle quantity.
|
Baseline, Week 12, and Week 24.
|
|
Change in Calf Circumference
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in calf circumference measured at the widest part of the calf using a soft tape.
It serves as a proxy indicator for lower limb muscle mass.
|
Baseline, Week 12, and Week 24.
|
|
Change in Gait Speed
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in gait speed using the 6-meter gait speed test.
Participants walk at a normal pace, and the time taken is recorded to reflect functional mobility.
|
Baseline, Week 12, and Week 24.
|
|
Change in Timed Up and Go (TUG) Test Time
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in the time required to rise from a chair, walk 3 meters, turn, return, and sit down again.
This test evaluates dynamic balance and agility.
|
Baseline, Week 12, and Week 24.
|
|
Change in Five Times Sit-to-Stand (5xSTS) Test Time
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in the time taken to complete five consecutive sit-to-stand cycles as quickly as possible.
This reflects lower limb muscle power and endurance.
|
Baseline, Week 12, and Week 24.
|
|
Change in Fried Frailty Phenotype Status
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in frailty status categorized as Robust (0 criteria), Pre-frail (1-2 criteria), or Frail (3-5 criteria) based on 5 indicators: grip strength, walking speed, exhaustion, weight loss, and physical activity.
|
Baseline, Week 12, and Week 24.
|
|
Change in Clinical Frailty Scale (CFS) Score
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in the Clinical Frailty Scale score, which ranges from 1 (Very Fit) to 9 (Terminally Ill).
It provides a holistic clinical assessment of frailty level.
|
Baseline, Week 12, and Week 24.
|
|
Change in Bone Mineral Density (BMD)
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in bone mineral density measured by Dual-energy X-ray Absorptiometry (DXA, Lunar iDXA).
|
Baseline, Week 12, and Week 24.
|
|
Change in Body Fat Percentage
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in body fat percentage analyzed using DXA (Lunar iDXA).
This reflects changes in body composition related to metabolic health.
|
Baseline, Week 12, and Week 24.
|
|
Change in SF-12 Quality of Life Score
Prazo: Baseline, Week 12, and Week 24.
|
Change from baseline in the 12-Item Short Form Health Survey (SF-12) scores.
Higher scores represent better health-related quality of life.
|
Baseline, Week 12, and Week 24.
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events (Safety)
Prazo: Baseline up to Week 24.
|
Number of participants with treatment-emergent adverse events (AEs) and serious adverse events (SAEs) .
AEs will be assessed for severity (mild, moderate, or severe) and their causal relationship to the study interventions (TCM formula or HMB supplement).
|
Baseline up to Week 24.
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities
Prazo: Baseline up to Week 24
|
Number of participants with laboratory values that are outside the reference range and judged by the investigator to be clinically significant.
Laboratory assessments include: Complete Blood Count (CBC); Liver function (ALT, AST, Albumin); Renal function (BUN, Creatinine, eGFR, Uric acid); Electrolytes (Na, K, Ca, Mg); Fasting blood glucose; and General Urinalysis (protein, glucose, urobilinogen, bilirubin, sediment, specific gravity, pH, occult blood) .
|
Baseline up to Week 24
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Jui-Shan Lin, MD, Tri-Service General Hospital
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146.
- Yoo JI, Choi H, Ha YC. Mean Hand Grip Strength and Cut-off Value for Sarcopenia in Korean Adults Using KNHANES VI. J Korean Med Sci. 2017 May;32(5):868-872. doi: 10.3346/jkms.2017.32.5.868.
- Soares LA, Lima LP, Prates ACN, Arrieiro AN, Da Costa Teixeira LA, Duarte TC, Dos Santos JM, da Silva Lage VK, de Paula FA, Costa HS, Figueiredo PHS, de Almeida VMTL, de Sara Abreu N, Costa SP, Brant FP, Lima RR, Thomasini RL, Pereira LSM, Pereira FSM, Parentoni AN, de Avelar NCP, Leopoldino AAO, Mendonca VA, Lacerda ACR. Accuracy of handgrip and respiratory muscle strength in identifying sarcopenia in older, community-dwelling, Brazilian women. Sci Rep. 2023 Jan 27;13(1):1553. doi: 10.1038/s41598-023-28549-5.
- Blanquet M, Ducher G, Sauvage A, Dadet S, Guiyedi V, Farigon N, Guiguet-Auclair C, Berland P, Bohatier J, Boirie Y, Gerbaud L. Handgrip strength as a valid practical tool to screen early-onset sarcopenia in acute care wards: a first evaluation. Eur J Clin Nutr. 2022 Jan;76(1):56-64. doi: 10.1038/s41430-021-00906-5. Epub 2021 Apr 13.
- Vaishya R, Misra A, Vaish A, Ursino N, D'Ambrosi R. Hand grip strength as a proposed new vital sign of health: a narrative review of evidences. J Health Popul Nutr. 2024 Jan 9;43(1):7. doi: 10.1186/s41043-024-00500-y.
- Dwimartutie N, Setiati S, Tamin TZ, Prijanti AR, Harahap AR, Purnamasari D, Harimurti K, Pramantara IDP, Suwarto S, Kojima T. Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial. Geriatr Gerontol Int. 2024 Jun;24(6):554-562. doi: 10.1111/ggi.14881. Epub 2024 Apr 21.
- Castell MV, Sanchez M, Julian R, Queipo R, Martin S, Otero A. Frailty prevalence and slow walking speed in persons age 65 and older: implications for primary care. BMC Fam Pract. 2013 Jun 19;14:86. doi: 10.1186/1471-2296-14-86.
- Nari F, Park EC, Nam CM, Jang SI. Impact of frailty on mortality and healthcare costs and utilization among older adults in South Korea. Sci Rep. 2023 Dec 1;13(1):21203. doi: 10.1038/s41598-023-48403-y.
- Alvarez-Bustos A, Rodriguez-Sanchez B, Carnicero-Carreno JA, Sepulveda-Loyola W, Garcia-Garcia FJ, Rodriguez-Manas L. Healthcare cost expenditures associated to frailty and sarcopenia. BMC Geriatr. 2022 Sep 13;22(1):747. doi: 10.1186/s12877-022-03439-z.
- Peng LN, Cheng YC, Yu PC, Lee WJ, Lin MH, Chen LK. Oral Nutritional Supplement with beta-hydroxy-beta-methylbutyrate (HMB) Improves Nutrition, Physical Performance and Ameliorates Intramuscular Adiposity in Pre-Frail Older Adults: A Randomized Controlled Trial. J Nutr Health Aging. 2021;25(6):767-773. doi: 10.1007/s12603-021-1621-7.
- Yang C, Song Y, Li T, Chen X, Zhou J, Pan Q, Jiang W, Wang M, Jia H. Effects of Beta-Hydroxy-Beta-Methylbutyrate Supplementation on Older Adults with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Study. J Nutr Health Aging. 2023;27(5):329-339. doi: 10.1007/s12603-023-1911-1.
- Takayama S, Tomita N, Arita R, Ono R, Kikuchi A, Ishii T. Kampo Medicine for Various Aging-Related Symptoms: A Review of Geriatric Syndrome. Front Nutr. 2020 Jul 15;7:86. doi: 10.3389/fnut.2020.00086. eCollection 2020.
- Buto MSS, de Oliveira MPB, Carvalho C, Vassimon-Barroso V, Takahashi ACM. Effect of complementary therapies on functional capacity and quality of life among prefrail and frail older adults: A systematic review of randomized controlled trials. Arch Gerontol Geriatr. 2020 Nov/Dec;91:104236. doi: 10.1016/j.archger.2020.104236. Epub 2020 Aug 21.
- Yakabe M, Hosoi T, Sasakawa H, Akishita M, Ogawa S. Kampo formula hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang, TJ-41) ameliorates muscle atrophy by modulating atrogenes and AMPK in vivo and in vitro. BMC Complement Med Ther. 2022 Dec 28;22(1):341. doi: 10.1186/s12906-022-03812-w.
- Schonenberg A, Heimrich KG, Sternkopf A, Lochbihler P, Prell T. Patient-reported geriatric syndromes and their association with quality of life: findings from a cross-sectional study in German older adults. Eur Geriatr Med. 2026 Apr;17(2):721-733. doi: 10.1007/s41999-025-01332-7. Epub 2025 Oct 16.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
2 de abril de 2026
Conclusão Primária (Estimado)
Conclusão Primária
31 de outubro de 2026
Conclusão do estudo (Estimado)
Conclusão do estudo
31 de dezembro de 2026
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
5 de maio de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
13 de maio de 2026
Primeira postagem (Real)
Primeira postagem
19 de maio de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
19 de maio de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
13 de maio de 2026
Última verificação
Última verificação
1 de maio de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças ósseas
- Doenças musculoesqueléticas
- Doenças do Sistema Nervoso
- Manifestações Neuromusculares
- Condições Patológicas, Anatômicas
- Doenças Metabólicas
- Doenças Ósseas Metabólicas
- Atrofia
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Sinais e sintomas
- Osteoporose
- Sarcopenia
- Atrofia Muscular
- Astenia
- ácido beta-hidroxiderovalérico
Outros números de identificação do estudo
Outros números de identificação do estudo
- MBS-101
- 115-1-N001 (Número de outro subsídio/financiamento: NRICM, MOHW)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Descrição do plano IPD
Individual participant data collected during the trial will not be shared with the general public.
According to the study protocol, all research data and intellectual property are jointly owned by the National Research Institute of Chinese Medicine and Tri-Service General Hospital.
To protect participant privacy and maintain strict confidentiality, access to de-identified participant data is limited to the principal investigator and authorized research team members.
Direct access to original records is permitted only for the trial sponsor, the Institutional Review Board, and regulatory authorities for the purposes of monitoring and auditing to ensure compliance with Good Clinical Practice and relevant data protection laws.
There is currently no plan to make the individual participant data available to external researchers or the public to maintain the highest standards of participant confidentiality and protect the research interests of the participating institutions.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .